APA

Rodríguez P. C., Prada D. M., Moreno E., Aira L. E., Molinero C., López A. M., Gómez J. A., Hernández I. M., Martínez J. P., Reyes Y., Milera J. M., Hernández M. V., Torres R., Avila Y., Barrese Y., Viada C., Montero E. & Hernández P. (20190128). The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. : Clinical and experimental immunology.

Chicago

Rodríguez P C, Prada D M, Moreno E, Aira L E, Molinero C, López A M, Gómez J A, Hernández I M, Martínez J P, Reyes Y, Milera J M, Hernández M V, Torres R, Avila Y, Barrese Y, Viada C, Montero E and Hernández P. 20190128. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. : Clinical and experimental immunology.

Harvard

Rodríguez P. C., Prada D. M., Moreno E., Aira L. E., Molinero C., López A. M., Gómez J. A., Hernández I. M., Martínez J. P., Reyes Y., Milera J. M., Hernández M. V., Torres R., Avila Y., Barrese Y., Viada C., Montero E. and Hernández P. (20190128). The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. : Clinical and experimental immunology.

MLA

Rodríguez P C, Prada D M, Moreno E, Aira L E, Molinero C, López A M, Gómez J A, Hernández I M, Martínez J P, Reyes Y, Milera J M, Hernández M V, Torres R, Avila Y, Barrese Y, Viada C, Montero E and Hernández P. The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. : Clinical and experimental immunology. 20190128.